Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/30096
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tishova, Y | - |
dc.contributor.author | Kalinchenko, S | - |
dc.contributor.author | Mskhalaya, G | - |
dc.contributor.author | Hackett, G | - |
dc.contributor.author | Livingston, M | - |
dc.contributor.author | König, C | - |
dc.contributor.author | Strange, R | - |
dc.contributor.author | Zitzmann, M | - |
dc.contributor.author | Mann, A | - |
dc.contributor.author | Maarouf, A | - |
dc.contributor.author | Ramachandran, S | - |
dc.date.accessioned | 2024-11-11T16:29:47Z | - |
dc.date.available | 2024-11-11T16:29:47Z | - |
dc.date.issued | 2024-03-03 | - |
dc.identifier | ORCiD: Carola König https://orcid.org/0000-0002-9289-3154 | - |
dc.identifier.citation | Tishova, Y. et al. (2024) 'Testosterone therapy reduces insulin resistance in men with adult-onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open-label phase', Diabetes, Obesity and Metabolism, 26 (6), pp. 2147 - 2157. doi: 10.1111/dom.15520. | en_US |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/30096 | - |
dc.description | Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request. | en_US |
dc.description.abstract | Aims: To describe changes in homeostasis model assessment of insulin resistance index (HOMA-IR) following testosterone therapy in men with hypogonadism and metabolic syndrome (MetS). Materials and Methods: A randomized, placebo-controlled, double-blind randomized controlled trial (RCT) comprising 184 men with MetS and hypogonadism (testosterone undecanoate [TU]: 113 men, placebo: 71 men) was conducted. This was followed by an open-label phase in which all men were given TU. We focused on men who were not receiving antiglycaemic agents (TU: 81 men; placebo: 54 men) as these could affect HOMA-IR. Inter-group comparison of HOMA-IR was restricted to the RCT (30 weeks), whilst intra-group comparison was carried out on men provided TU during the RCT and open-label phases (study cohort) and men given placebo during the RCT and then switched to TU during the open-label phase (confirmatory cohort). Regression analysis was performed to identify factors associated with change in HOMA-IR (∆HOMA-IR). Results: The median HOMA-IR was significantly reduced at almost every time point (after 18 weeks) compared to baseline in men receiving TU in both the study and confirmatory cohorts. There was a significant decrease in median values of fasting glucose (30 weeks: −2.1%; 138 weeks: −4.9%) and insulin (30 weeks: −10.5%; 138 weeks: −35.5%) after TU treatment. Placebo was not associated with significant ∆HOMA-IR. The only consistent predictor of HOMA-IR decrease following TU treatment was baseline HOMA-IR (r2 ≥ 0.64). Conclusions: Baseline HOMA-IR predicted ΔHOMA-IR, with a greater percentage change in insulin than in fasting glucose. In men with MetS/type 2 diabetes (T2DM) not on antiglycaemic therapy, improvements in HOMA-IR may be greater than suggested by change in fasting glucose. Our results suggest that hypogonadism screening be included in the management of men with MetS/T2DM. | en_US |
dc.description.sponsorship | North Staffordshire Medical Institute. Grant Number: PID-200078 | en_US |
dc.format.extent | 2147 - 2157 | - |
dc.format.medium | Print-Electronic | - |
dc.language | English | - |
dc.language.iso | en_US | en_US |
dc.publisher | Wiley | en_US |
dc.rights | Attribution-NonCommercial 4.0 International | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | - |
dc.subject | adult-onset hypogonadism | en_US |
dc.subject | insulin resistance | en_US |
dc.subject | metabolic syndrome | en_US |
dc.subject | testosterone therapy | en_US |
dc.subject | waist circumference | en_US |
dc.title | Testosterone therapy reduces insulin resistance in men with adult-onset testosterone deficiency and metabolic syndrome. Results from the Moscow Study, a randomized controlled trial with an open-label phase | en_US |
dc.type | Article | en_US |
dc.date.dateAccepted | 2024-02-11 | - |
dc.identifier.doi | https://doi.org/10.1111/dom.15520 | - |
dc.relation.isPartOf | Diabetes, Obesity and Metabolism | - |
pubs.issue | 6 | - |
pubs.publication-status | Published | - |
pubs.volume | 26 | - |
dc.identifier.eissn | 1463-1326 | - |
dc.rights.license | https://creativecommons.org/licenses/by-nc/4.0/legalcode.en | - |
dc.rights.holder | The Authors | - |
Appears in Collections: | Dept of Mechanical and Aerospace Engineering Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | Copyright © 2024 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | 1.13 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License